前沿生物-U
(688221)
| 流通市值：82.41亿 | | | 总市值：82.41亿 |
| 流通股本：3.75亿 | | | 总股本：3.75亿 |
| 报告期 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 297,131,734.61 | 123,386,656.86 | 103,373,939.22 | 58,639,825.88 |
| 营业收入 | 297,131,734.61 | 123,386,656.86 | 103,373,939.22 | 58,639,825.88 |
| 二、营业总成本 | 74,623,130.61 | 378,879,481.97 | 262,354,974.69 | 159,170,063.11 |
| 营业成本 | 17,809,313.51 | 82,399,968.22 | 67,356,219.4 | 40,468,036.68 |
| 税金及附加 | 967,180.45 | 3,278,295.6 | 2,385,541.78 | 1,564,162.01 |
| 销售费用 | 17,116,599.35 | 86,747,523 | 65,858,144.17 | 37,676,114.99 |
| 管理费用 | 14,929,216.38 | 65,008,777.59 | 43,902,955.74 | 32,416,374.22 |
| 研发费用 | 23,613,376 | 141,536,096.24 | 83,870,664.18 | 47,936,469.2 |
| 财务费用 | 187,444.92 | -91,178.68 | -1,018,550.58 | -891,093.99 |
| 其中:利息费用 | 2,298,490.93 | 9,112,329.26 | 6,817,412.49 | 4,670,816.41 |
| 其中:利息收入 | 1,517,403.22 | 10,086,090.48 | 8,420,692.35 | 5,901,767.72 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | 24,571.88 | -546,697.65 | -725,728.39 | -297,011.44 |
| 加:投资收益 | 3,931,808.14 | -1,062,974.77 | -5,778,666.97 | -1,861,944.89 |
| 资产处置收益 | -92.92 | -26,728.07 | -22,430.99 | 15,353.93 |
| 资产减值损失(新) | -2,026,270.67 | -2,866,584.85 | -1,576,076.24 | -89,923.13 |
| 信用减值损失(新) | -151,323.84 | -22,286,894.29 | -2,802,286.87 | -1,443,018.17 |
| 其他收益 | 3,357,749.1 | 14,562,090.65 | 10,410,236.6 | 7,058,376.99 |
| 四、营业利润 | 227,645,045.69 | -267,720,614.09 | -159,475,988.33 | -97,148,403.94 |
| 加:营业外收入 | 3,215.04 | 44,617.44 | 23,101.96 | 21,040.01 |
| 减:营业外支出 | 254,506.55 | 377,035.38 | 355,639.7 | 225,246.75 |
| 五、利润总额 | 227,393,754.18 | -268,053,032.03 | -159,808,526.07 | -97,352,610.68 |
| 六、净利润 | 227,393,754.18 | -268,053,032.03 | -159,808,526.07 | -97,352,610.68 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 227,393,754.18 | -268,053,032.03 | -159,808,526.07 | -97,352,610.68 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 227,393,754.18 | -268,053,032.03 | -159,808,526.07 | -97,352,610.68 |
| 扣除非经常损益后的净利润 | 219,268,704.42 | -302,303,357.09 | -185,228,750.55 | -114,735,072.42 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 0.61 | -0.72 | -0.43 | -0.26 |
| (二)稀释每股收益 | 0.61 | -0.72 | -0.43 | -0.26 |
| 八、其他综合收益 | 40,776.3 | 15,381.27 | 17,530.76 | 16,756.4 |
| 归属于母公司股东的其他综合收益 | 40,776.3 | 15,381.27 | 17,530.76 | 16,756.4 |
| 九、综合收益总额 | 227,434,530.48 | -268,037,650.76 | -159,790,995.31 | -97,335,854.28 |
| 归属于母公司股东的综合收益总额 | 227,434,530.48 | -268,037,650.76 | -159,790,995.31 | -97,335,854.28 |
| 公告日期 | 2026-04-25 | 2026-04-25 | 2025-10-31 | 2025-08-30 |
| 审计意见(境内) | | 标准无保留意见 | | |